STOCK TITAN

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

No Shareholder Action Required at This Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.

Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.

There is no guarantee that any transaction will result from Biogen’s proposal. Sage’s shareholders do not need to take any action at this time.

About Sage Therapeutics

Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

Investor Contact

Ashley Kaplowitz

Ashley.Kaplowitz@sagerx.com



Media Contacts

Francesca Dellelci

Francesca.Dellelci@sagerx.com



Tim Lynch / Jed Repko

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449

Source: Sage Therapeutics, Inc.

Sage Therapeutic

NASDAQ:SAGE

SAGE Rankings

SAGE Latest News

SAGE Stock Data

456.80M
54.09M
11.94%
79.96%
6.37%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE